Concepedia

Peter G. Tarassoff

PG

16

Publications

8.7K

Citations

15

H-Index

1978

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Eli Lilly (United States)

Memorial Sloan Kettering Cancer Center

The University of Texas Health Science Center at San Antonio

Walter Reed Army Institute of Research

Peter G. Tarassoff is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

Top concepts

Publications per year

1978–2023

16

Publications

16

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.8K citations

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 757 citations

, , +12

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Mace L. Rothenberg, Malcolm J. Moore, M. Christine Cripps et al. · Annals of Oncology · 1996 · 569 citations · Full text

, , +7

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen et al. · Investigational New Drugs · 1994 · 440 citations

, , +5

Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

Ralf Grunewald, James L. Abbruzzese, Peter G. Tarassoff et al. · Cancer Chemotherapy and Pharmacology · 1991 · 249 citations

, , +6

Rows per page

1–5 of 16